Sanofi (SNY)

FR — Healthcare Sector
Peers: AZN  RHHBY  GSK  MRK  NVS  BMY  GILD  BAYRY  AMGN  ABBV  JNJ 

Automate Your Wheel Strategy on SNY

With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SNY
  • Rev/Share 35.4761
  • Book/Share 60.3112
  • PB 0.7972
  • Debt/Equity 0.2841
  • CurrentRatio 1.3662
  • ROIC 0.0604

 

  • MktCap 116608872127.0
  • FreeCF/Share 1.2878
  • PFCF 73.3851
  • PE 9.3752
  • Debt/Assets 0.1596
  • DivYield 0.0462
  • ROE 0.0848

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SNY Exane BNP Paribas -- Outperform -- $65 April 15, 2025
Initiation SNY Goldman -- Neutral -- $65 March 21, 2025
Upgrade SNY Deutsche Bank Sell Hold -- -- Jan. 30, 2025

News

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
BPMC, SNY
Published: June 20, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive t.

Read More
image for news BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
REGN, SNY
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive

SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.

Read More
image for news Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
MRK, PFE, SNY
Published: June 18, 2025 by: Reuters
Sentiment: Neutral

U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.

Read More
image for news RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
MRK, PFE, SNY
Published: June 18, 2025 by: CNBC
Sentiment: Neutral

A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.

Read More
image for news RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SNY
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
ABBV, BAYRY, NVS, PFE, SNY
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral

In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.

Read More
image for news 5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SNY
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca
MRK, SNY
Published: June 09, 2025 by: CNBC
Sentiment: Positive

The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter.

Read More
image for news FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SNY
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SNY
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
SNY
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries.

Read More
image for news Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SNY
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
SNY
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.

Read More
image for news SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
SNY
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusion Studies used Enable Injections' enFuse® on-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatment Paris, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in …

Read More
image for news Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
BMY, BNTX, BPMC, MRK, SNY
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

Read More
image for news Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
BPMC, SNY
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive

SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.

Read More
image for news Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
BPMC, SNY
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY).

Read More
image for news Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
Sanofi-Blueprint deal is a bullish signal about biotech M&A
SNY
Published: June 02, 2025 by: Yahoo Finance
Sentiment: Positive

The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. Sanofi is set to buy Blueprint Medicines for over $9 billion, while Bristol-Myers Squibb plans to license a cancer drug from BioNTech.

Read More
image for news Sanofi-Blueprint deal is a bullish signal about biotech M&A
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
SNY
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi

Read More
image for news Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
SNY
Published: June 02, 2025 by: Reuters
Sentiment: Positive

French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.

Read More
image for news Sanofi buys US biopharma group Blueprint in $9.1 bln deal
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
BPMC, SNY
Published: June 02, 2025 by: WSJ
Sentiment: Positive

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

Read More
image for news Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
BPMC, SNY
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Read More
image for news Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
BPMC, SNY
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Read More
image for news Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
BPMC, SNY
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Read More
image for news Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Itepekimab Failure A Setback For Sanofi And Regeneron
REGN, SNY
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Negative

Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab. Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.

Read More
image for news Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
REGN, SNY
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

Read More
image for news Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
SNY
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral

MORRISTOWN, N.J. , May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.

Read More
image for news Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
SNY
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.

Read More
image for news Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
Sanofi to Buy Vigil Neuroscience for About $470 Million
SNY, VIGL
Published: May 21, 2025 by: WSJ
Sentiment: Positive

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer's disease to the French pharmaceutical company's pipeline.

Read More
image for news Sanofi to Buy Vigil Neuroscience for About $470 Million
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
VIGL, SNY
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 -

Read More
image for news Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

About Sanofi (SNY)

  • IPO Date 2002-07-01
  • Website https://www.sanofi.com
  • Industry Drug Manufacturers - General
  • CEO Mr. Paul Hudson
  • Employees 82878

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.